GlobeNewswire by notified

Flerie Invest leder förvärv av norrländsk läkemedelsfabrik för 455 miljoner kronor

Dela

Storsatsning på DNA, RNA, protein och avancerad läkemedelsutveckling och GMP-tillverkning

STOCKHOLM, Sweden, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Flerie Invest, ett investmentbolag inom bioteknik- och läkemedelsutveckling med kontor i Stockholm och London, har lett ett syndikat av investerare och förvärvat Cobra Biologics verksamhet i Matfors, Sverige, från det amerikanska företaget Charles River Laboratories. Köpeskillingen uppgår till cirka 455 miljoner kronor samt ytterligare villkorad köpeskilling senare. Verksamheten har 128 anställda som alla erbjuds fortsatt anställning. Verksamheten kommer fortsättningsvist att bedrivas under namnet NorthX Biologics.

Anläggningen i Matfors omfattar en yta på 7’000 kvadrameter och har en befintlig renrumsinfrastruktur, processutvecklings- och kvalitetskontrolllaboratorier samt lagerutrymmen och är utrustad för att tillverka plasmid-DNA enligt GMP och teknisk proteintillverkning i kommersiell skala. Ytterligare investeringar och utvidgning av anläggningen kommer att påbörjas och detta förväntas leda till ökat antal anställda. Detta kommer att resultera i ökad biofarmaceutisk utveckling och tillverkningskapacitet, inklusive RNA- och cellterapier, och kommer att katalysera FoU- och tillverkningspartnerskap i Norden, vidare inom EU och resten av världen.

”Detta förvärv är en ambitiös satsning för oss och passar bra med Fleries strategi att investera i gen- och cellterapirområdet i Europa och USA,” säger Thomas Eldered, President för Flerie Invest.

”Jag ser fram emot att arbeta med den mycket kompetenta personalen i Matfors för att hjälpa innovativa biotechbolag att växa, samt att skapa beredskap och produktionstrygghet för läkemedel och vacciner inför framtida pandemier”, säger Ted Fjällman, partner Flerie Invest och VD för NorthX Biologics.

Om Flerie Invest AB

Flerie Invest är ett svenskt investmentbolag inom bioteknologi och läkemedel med kontor i Stockholm och London. Portföljen består av mer än 16 bolag i Sverige, Storbritannien, USA, Nederländerna, Island och Israel. Fokus ligger på investeringar i bolag inom läkemedelsutveckling. Bolaget grundades 2010 av Thomas Eldered, medgrundare till Recipharm som han byggde upp till ett av fem globalt ledande bolag inom kontraktstillverkning av läkemedel. Flerie Invest är en aktiv medlem i SwedenBIO och British Venture Capital Association (BVCA).

För mer information kontakta:

Thomas Eldered, President Flerie Invest, contact(at)flerie.com, +46 (0)8 55921870
Ted Fjällman, VD NorthX Biologics, media(at)nxbio.com, +46 (0)8 55926888



För att se det här innehållet från www.globenewswire.com måste du ge ditt medgivande sidans topp.
För att se det här innehållet från ml.globenewswire.com måste du ge ditt medgivande sidans topp.

Om

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Följ GlobeNewswire by notified

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire by notified

HMNC Brain Health to Participate in the H.C. Wainwright 2nd Annual Psychedelics Conference1.12.2021 16:37:31 CET | Press release

MUNICH, Germany, Dec. 01, 2021 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC” or the “company”), a clinical stage biopharma company pioneering the development of personalized therapies powered by predictive companion diagnostics, announced today that Chief Executive Officer, Benedikt von Braunmühl, Chief Clinical Development Officer, Dr. Hans Eriksson and Head of Operations, Dr. Maximilian Döbler will present at H.C. Wainwright’s 2nd Annual Psychedelics Conference on Monday, December 6th, 2021. In addition, Dr. Eriksson will participate in the ‘Future of Mental Healthcare’ panel at 2:30 p.m. Eastern Time. To attend, please register here. HMNC Brain Health’s virtual presentation will be available beginning Monday, December 6th at 7:00 a.m. Eastern Time and is accessible through the following webcast link: https://journey.ct.events/view/d77f2d7d-bff2-4d9a-8e89-620a24d1f35a. A webcast of the presentation will be available on the HMNC Brain Health Website for 90 days through the above webca

4TEEN4 Pharmaceuticals Selects AGC Biologics to Manufacture Procizumab1.12.2021 15:03:00 CET | Press release

AGC Biologics to produce Procizumab for early and late clinical phases at company’s Chiba and Copenhagen facilities Seattle, Dec. 01, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with 4TEEN4 Pharmaceuticals GmbH (“4TEEN4”) to manufacture and commercialize Procizumab. The first-in-class monoclonal antibody Procizumab offers a new approach for the treatment of life-threatening diseases related to acute circulatory failure. Under the terms of the agreement, the companies will collaborate to transfer and optimize the manufacturing process for Procizumab. AGC Biologics will manufacture the clinical trial materials at its site in Chiba and transfer to its Copenhagen facility for all late phase activities including commercialization, to support early and late clinical phases and launch readiness of 4TEEN4’s monoclonal antibody. “We look forward to partnering with 4TEEN4

Kalmar’s proven straddle carrier technology to enhance operational capabilities at Kingston Freeport Terminal, Jamaica1.12.2021 15:00:00 CET | Press release

CARGOTEC CORPORATION, PRESS RELEASE, 1 DECEMBER 2021 AT 4 PM (EET) Kalmar, part of Cargotec, has signed a contract to supply the Kingston Freeport Terminal Limited (KFTL) with four diesel-electric straddle carriers for use at their terminal in Kingston, Jamaica. The order was booked in Cargotec's 2021 Q4 order intake with delivery scheduled to be completed during Q3 2022. KFTL is a strategic transhipment hub in the Caribbean, located at the exit of the Panama Canal and the crossroads of the North/South and East/West lines. The terminal was established in 2015, and it is part of Terminal Link, a joint venture between The CMA CGM Group, a world leader in shipping and logistics, and China Merchants Port (CMP). The four Kalmar Straddle Carriers are part of a progressive fleet renewal strategy geared to improve performance and reliability in the terminal's operation. KFTL’s equipment fleet already includes Kalmar straddle carriers, reachstackers, empty container handlers and terminal tracto

Sinch carries out second part of the directed new share issue of approximately 40 million shares announced on 30 September 20211.12.2021 14:50:00 CET | Press release

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, NEW ZEALAND, HONG KONG, SINGAPORE OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE MAY BE UNLAWFUL, WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES Stockholm, Sweden – December 1, 2021 - Sinch AB (publ) (“Sinch” or the “Company”) carries out a directed new share issue through the issuance of 21 million new shares for a total consideration of approximately SEK 3,469 million. The new share issue constitutes the second part of the SEK 6.6 billion new share issue of in total 40,077,841 shares (the “Shares”) announced on 30 September 2021, the proceeds of which are used to partially fund the acquisition of Pathwire. The subscribers consisted of institutional investors, among others the Canada Pension Plan Investment Board (“CPP Investments”), Temasek, SeaTown Master Fund (“SeaTown”), and SB Northstar LP,

Sinch genomför den andra delen av den riktade nyemissionen om cirka 40 miljoner aktier som offentliggjordes den 30 september 20211.12.2021 14:50:00 CET | Pressemelding

EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUERING ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, I ELLER TILL USA, KANADA, JAPAN, AUSTRALIEN, SYDAFRIKA, NYA ZEELAND, HONGKONG, SINGAPORE ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTIONEN ELLER PUBLICERING AV DETTA PRESSMEDDELANDE SKULLE KUNNA VARA OLAGLIG, KRÄVA YTTERLIGARE REGISTRERING ELLER ANDRA ÅTGÄRDER Stockholm, Sverige – 1 december 2021 – Sinch AB (publ) (“Sinch” eller “Bolaget”) genomför en riktad nyemission av 21 miljoner aktier mot en total teckningslikvid om cirka 3,469 miljarder kronor. Nyemissionen utgör den andra delen av den riktade nyemissionen om totalt cirka 6,6 miljarder kronor av 40 077 841 aktier (”Aktierna”) som offentliggjordes den 30 september 2021. Emissionslikviden från den riktade nyemissionen används för att delfinansiera förvärvet av Pathwire. Tecknarna bestod av institutionella investerare, däribland Canada Pension Plan Investment Board (”CPP Investments”), Temasek, SeaTown Master Fund (”Seatown

Voyager Closes Series A Funding, Marking $10M Raised1.12.2021 14:00:00 CET | Press release

Investment to fuel growth across the marine supply chain HOUSTON, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Voyager Portal, a software platform enabling companies to reduce cost, risk, and complexity in their marine supply chain, has today announced an $8.4 million Series A investment, led by Phaze Ventures. Other new investors include ScOp Venture Capital, Waybury Capital and Flexport. All existing investors followed in on this round. The new funding comes on the back of unprecedented growth since the company raised $1.5 million in seed money two years ago. Since then, revenue has increased 13x from Q3 2020 to Q3 2021 and was up 40% from Q2 2021. Additionally, Voyager surpassed the $1 billion-mark for freight managed on the platform. Voyager's customers include manufacturers, traders and shippers in the renewable energy, commodity trading, mining and petrochemicals industries. “Voyager Portal was created to significantly reduce cost, risk, and complexity when transporting bulk materials aroun

Agreements entered into regarding the sale of three Volvo facilities in Norway1.12.2021 13:40:00 CET | Press release

Bilia has today, as part of the agreement with Volvo Cars dated 1 October 2021, entered into agreements to sell three facilities in Norway, in the Oslo area, to the newly established company Volvo Car Stor-Oslo AS. The three facilities are located in Økern, Fornebu and Lillestrøm and conduct sales of new cars, used cars and service for Volvo cars. The sale is expected to take place on 1 July 2022. The transfer is subject to approval by the Norwegian competition authority. Gothenburg, December 1, 2021 Bilia AB (publ) For information please contact: Per Avander, Managing Director and CEO, +46 (0)10 497 70 00, per.avander@bilia.se Kristina Franzén, CFO, +46 (0)10 497 73 40, kristina.franzen@bilia.se Facts about the Bilia Group Bilia is one of Europe’s largest car dealers with a leading position within service and sales of cars, transport vehicles and trucks. Bilia has about 160 facilities in Sweden, Norway, Germany, Luxembourg and Belgium. Bilia sells cars of the brand Volvo, BMW, Toyota,